Related Experiment Video
Updated: Dec 5, 2025

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
La prévention pré-exposition au VIH-1 par les antirétroviraux, la PrEP
Constance Delaugerre1, Caroline Gatey2, Marie-Laure Chaix1
1AP-HP, Hôpital Saint-Louis, Laboratoire de virologie, 1, avenue Claude-Vellefaux, 75010 Paris, France, Université Paris-Diderot, Hôpital Saint-Louis, IUH, Inserm U941, Paris, France.
Abstract:
Due to the lack of vaccine, the HIV epidemic is still uncontrolled. Use of antiretrovirals (ARV) for prevention, successfully implemented to prevent mother-to-child transmission of HIV, is a new avenue to control the epidemic. One approach is to treat all patients diagnosed with HIV, and suppress viremia and transmission to their partner. Another strategy is the use of ARV as a pre-exposition prophylaxis (PrEP) in HIV-negative at risk individuals. Oral tenofovir (TDF) ± emtricitabine (FTC) is the elected drug regimen for PrEP, given its safety, its long intracellular half-life and a high diffusion into mucosal entry sites. PrEP was investigated in randomized trials of oral or local gel given daily or at time of sexual intercourse in high-risk populations. PrEP efficacy is strongly correlated to adherence and concentrations of ARV. Adverse events have been infrequent. Selection of FTC-resistant strains has been mainly reported in undiagnosed HIV-infected participants using PrEP. PrEP is now strongly recommended by WHO in prevention programs for HIV in order to control the epidemic by 2030.
More Related Videos
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
12:03Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
Published on: September 5, 2016
Related Concept Videos
Retrovirus Life Cycles
Sexually Transmitted Infections
Retroviruses